Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment...
Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
About this item
Full title
Author / Creator
Publisher
England: Blackwell Publishing Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Blackwell Publishing Ltd
Subjects
More information
Scope and Contents
Contents
Aims
To assess the long‐term safety of subcutaneous buprenorphine (CAM2038) weekly and monthly depots.
Design
Phase 3, open‐label, observational, multi‐centre 48‐week trial (ClinicalTrials.gov NCT02672111).
Setting
Twenty‐six out‐patient sites (United States, United Kingdom, Hungary, Denmark, Sweden, Germany, Australia) between 14 De...
Alternative Titles
Full title
Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6771955
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6771955
Other Identifiers
ISSN
0965-2140
E-ISSN
1360-0443
DOI
10.1111/add.14636
